429 related articles for article (PubMed ID: 20606731)
1. Expression of fatty acid synthase in nonalcoholic fatty liver disease.
Dorn C; Riener MO; Kirovski G; Saugspier M; Steib K; Weiss TS; Gäbele E; Kristiansen G; Hartmann A; Hellerbrand C
Int J Clin Exp Pathol; 2010 Mar; 3(5):505-14. PubMed ID: 20606731
[TBL] [Abstract][Full Text] [Related]
2. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
3. Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice.
Rom O; Xu G; Guo Y; Zhu Y; Wang H; Zhang J; Fan Y; Liang W; Lu H; Liu Y; Aviram M; Liu Z; Kim S; Liu W; Wang X; Chen YE; Villacorta L
EBioMedicine; 2019 Mar; 41():62-72. PubMed ID: 30772307
[TBL] [Abstract][Full Text] [Related]
4. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.
O'Farrell M; Duke G; Crowley R; Buckley D; Martins EB; Bhattacharya D; Friedman SL; Kemble G
Sci Rep; 2022 Sep; 12(1):15661. PubMed ID: 36123383
[TBL] [Abstract][Full Text] [Related]
5. Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation.
Kirovski G; Gäbele E; Dorn C; Moleda L; Niessen C; Weiss TS; Wobser H; Schacherer D; Buechler C; Wasmuth HE; Hellerbrand C
Int J Clin Exp Pathol; 2010 Aug; 3(7):675-80. PubMed ID: 20830238
[TBL] [Abstract][Full Text] [Related]
6. Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling.
Xie Y; Shen F; He Y; Guo C; Yang R; Cao H; Pan Q; Fan J
Nutrients; 2023 Mar; 15(5):. PubMed ID: 36904254
[TBL] [Abstract][Full Text] [Related]
7. Dietary Mung Bean Protein Reduces Hepatic Steatosis, Fibrosis, and Inflammation in Male Mice with Diet-Induced, Nonalcoholic Fatty Liver Disease.
Watanabe H; Inaba Y; Kimura K; Asahara SI; Kido Y; Matsumoto M; Motoyama T; Tachibana N; Kaneko S; Kohno M; Inoue H
J Nutr; 2017 Jan; 147(1):52-60. PubMed ID: 27903831
[TBL] [Abstract][Full Text] [Related]
8. Histone modifications in fatty acid synthase modulated by carbohydrate responsive element binding protein are associated with non‑alcoholic fatty liver disease.
Cai C; Yu H; Huang G; Du X; Yu X; Zhou Y; Shen W
Int J Mol Med; 2018 Sep; 42(3):1215-1228. PubMed ID: 29786745
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model.
Kong M; Zhu L; Bai L; Zhang X; Chen Y; Liu S; Zheng S; Pandol SJ; Han YP; Duan Z
Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(9):G883-93. PubMed ID: 25214402
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
11. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways.
Larter CZ; Yeh MM; Haigh WG; Williams J; Brown S; Bell-Anderson KS; Lee SP; Farrell GC
J Hepatol; 2008 Apr; 48(4):638-47. PubMed ID: 18280001
[TBL] [Abstract][Full Text] [Related]
12. Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models.
Matsukawa T; Yagi T; Uchida T; Sakai M; Mitsushima M; Naganuma T; Yano H; Inaba Y; Inoue H; Yanagida K; Uematsu M; Nakao K; Nakao H; Aiba A; Nagashima Y; Kubota T; Kubota N; Izumida Y; Yahagi N; Unoki-Kubota H; Kaburagi Y; Asahara SI; Kido Y; Shindou H; Itoh M; Ogawa Y; Minami S; Terauchi Y; Tobe K; Ueki K; Kasuga M; Matsumoto M
JCI Insight; 2023 Sep; 8(17):. PubMed ID: 37681411
[TBL] [Abstract][Full Text] [Related]
13. TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase.
Xu S; Wu X; Wang S; Xu M; Fang T; Ma X; Chen M; Fu J; Guo J; Tian S; Tian T; Cheng X; Yang H; Zhou J; Wang Z; Yin Y; Xu W; Xu F; Yan J; Wang Z; Luo S; Zhang XJ; Ji YX; Weng J
J Clin Invest; 2024 Jan; 134(5):. PubMed ID: 38206764
[TBL] [Abstract][Full Text] [Related]
14. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
18. TAF15 exacerbates nonalcoholic steatohepatitis progression by regulating lipid metabolism and inflammation via FASN and p65 NF-κB.
Yang S; Xu B; Han Y; Jiang M; Luo T; Wu N; Cao J; Zheng Y; Shen L; Qin W; Shi H; Dong L
Liver Int; 2023 Sep; 43(9):1920-1936. PubMed ID: 37183512
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease.
Charlton M; Viker K; Krishnan A; Sanderson S; Veldt B; Kaalsbeek AJ; Kendrick M; Thompson G; Que F; Swain J; Sarr M
Hepatology; 2009 Apr; 49(4):1375-84. PubMed ID: 19330863
[TBL] [Abstract][Full Text] [Related]
20. A Nutraceutical Formulation Containing Brown Algae Reduces Hepatic Lipid Accumulation by Modulating Lipid Metabolism and Inflammation in Experimental Models of NAFLD and NASH.
Gabbia D; Roverso M; Zanotto I; Colognesi M; Sayaf K; Sarcognato S; Arcidiacono D; Zaramella A; Realdon S; Ferri N; Guido M; Russo FP; Bogialli S; Carrara M; De Martin S
Mar Drugs; 2022 Sep; 20(9):. PubMed ID: 36135761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
